Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705933 | 0.91 | IDO1 (0.33) | TTKMAPK13WDR5P2RY14CNR1 | |
| SCHEMBL18706315 | 0.91 | P2RY14 (0.43) | P2RY14 | |
| SCHEMBL18706466 | 0.91 | HSD11B1 (0.36) | P2RY14P2RX3P2RX2TYRO3CNR1 | |
| SCHEMBL18706206 | 0.89 | P2RY14 (0.42) | TTKP2RY14FGFR1CNR2 | |
| SCHEMBL18706534 | 0.87 | DGAT1 (0.35) | TTKMAPK13WDR5P2RY14HPGDS | |
| SCHEMBL18706279 | 0.86 | POLB (0.37) | TTKP2RY14P2RX3P2RX2FGFR1 | |
| SCHEMBL18706478 | 0.86 | CNR2 (0.42) | TTKP2RY14CNR1CNR2 | |
| SCHEMBL18172501 | 0.85 | P2RX3 (0.37) | TTKWDR5P2RY14P2RX3P2RX2 | |
| SCHEMBL18285359 | 0.85 | TTK (0.38) | TTKMAPK13WDR5P2RX3P2RX2 | |
| SCHEMBL18706012 | 0.84 | WDR5 (0.37) | TTKWDR5P2RY14HPGDSTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137566-B | Triazole derivatives | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | claimed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | claimed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | claimed |
| CN-108137566-B | Triazole derivatives | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | MC2R, MC3R, OXTR | TTK 1925/4885MAPK13 2764/4885WDR5 2218/4885 |
| US-10273217-B2 | Triazole derivatives | MC2R, MC3R, OXTR | TTK 1925/4885MAPK13 2764/4885WDR5 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.